Progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA) are devastating neurodegenerative disorders with no effective treatments and limited research funding. Congressional advocacy for these rare diseases could accelerate research into tau protein pathology and alpha-synuclein dysfunction, potentially benefiting broader neurodegenerative disease understanding.
CurePSP organized a bipartisan congressional briefing to advocate for increased research funding for three rare neurodegenerative diseases: PSP, CBD, and MSA. These conditions collectively affect tens of thousands of Americans and share pathological features including abnormal protein aggregation (tau in PSP and CBD, alpha-synuclein in MSA). All three diseases have rapid progression, poor prognosis, and no disease-modifying treatments. The briefing aimed to raise awareness about research needs and potential therapeutic targets.
“While this briefing focuses on neurological CBD rather than cannabidiol, it highlights how rare disease advocacy can drive research funding. The tau and alpha-synuclein pathways these diseases target may eventually inform broader neurodegenerative therapeutics.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is the clinical relevance rating for this cannabis research?
This research has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests emerging findings or policy developments that are worth monitoring closely by healthcare professionals.
What medical conditions does this cannabis research focus on?
The research primarily focuses on neurodegenerative diseases and movement disorders. It also relates to rare disease conditions that may benefit from cannabis-based treatments.
Is this research advocacy or clinical study data?
Based on the tags, this appears to be research advocacy content rather than completed clinical trial results. It likely discusses the need for more research or policy changes in cannabis medicine for neurological conditions.
Why is this cannabis news considered “new” and noteworthy?
The article is marked as “New” content with notable clinical interest, suggesting recent developments in cannabis research for neurological conditions. These emerging findings warrant close monitoring by the medical community.
Who should pay attention to this cannabis research update?
Healthcare professionals treating patients with neurodegenerative diseases, movement disorders, and rare conditions should monitor this research. Clinicians involved in cannabis medicine and neurological care would find this particularly relevant.
Read next
